Clinical trials · Massachusetts
ER Positive Breast Cancer clinical trials in Massachusetts
We’re tracking 43 recruiting er positive breast cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06590857RecruitingPhase 1/Phase 2
Study of targeted radiation for advanced breast cancer
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Boston, MassachusettsAges Any age - NCT07482384Recruiting
Support program for young women with early-stage breast cancer
This study tests a mobile health program that provides support and information to young women with early-stage breast cancer who are on hormone therapy. The goal is to help you stay on your treatment and manage side effects.
Boston, MassachusettsAges 18–49 - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Boston, MassachusettsAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Boston, MassachusettsAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Burlington, MassachusettsAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Needham, MassachusettsAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Boston, MassachusettsAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Boston, MassachusettsAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Danvers, MassachusettsAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Boston, MassachusettsAges 18 years+ - NCT06123988Recruiting
Fasting and exercise for advanced breast cancer
This study looks at whether fasting overnight and/or doing exercise can help improve fatigue and other quality-of-life measures in women with advanced hormone receptor positive breast cancer who are already taking a CDK4/6 inhibitor. Participation may involve following a fasting or exercise plan for a period of time.
Boston, MassachusettsAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Boston, MassachusettsAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Peabody, MassachusettsAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Beverly, MassachusettsAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Stoneham, MassachusettsAges 18–60 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Stoneham, MassachusettsAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Boston, MassachusettsAges 18–130 - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Boston, MassachusettsAges 18 years+ - NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
Boston, MassachusettsAges 18 years+
ER Positive Breast Cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting er positive breast cancer studies listed above.
- Dana-Farber Cancer Institute · 14 studies
- Beth Israel Deaconess Medical Center · 7 studies
- Lahey Hospital and Medical Center · 5 studies
- Massachusetts General Hospital · 5 studies
- Lahey Medical Center Peabody · 4 studies
- Addison Gilbert Hospital · 3 studies
- Baystate Medical Center · 3 studies
- Beverly Hospital · 3 studies
What taking part in a er positive breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
ER Positive Breast Cancer trials in other states
Common questions
- Are there er positive breast cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 43 recruiting er positive breast cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a er positive breast cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New er positive breast cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.